[moc::"[[MOC Special Topics - Lung]]"]
>[!title]
> R0, N+: [PORT Meta '98,](https://www.sciencedirect.com/science/article/pii/S0140673698063417?via%3Dihub) ['16](https://www.ncbi.nlm.nih.gov/pubmed/27684386): 

>[!intervention]
> Surgery {± PORT}

# Study
- 11 RCTs with 2,343 patients #pimp 
	- resected #pimp 
	- stage I-IIIA NSCLC.
	- 25% T1N0.
	- primary outcome: OS #pimp
- Treatment
	- 80% Cobalt. Majority 2D. Larger fields.
	- Heart often in the field. Patients are commonly dying from cardiac comorbidities.

# Results
- Relative risk of LR reduced by 24% for all stages combined.
- 2y OS 58→ 53% 
	- HR 0.87: **favors omission of RT**

# Notes
- old data, old RT
- 

![[img_Meta-analysis Trialists Group_results1.png#invert]]

>[!summary]
> Inferior OS benefit unless III or N2. 
> Criticism: now we have better staging (MRI brain, PET, EBUS), better chemo, and better RT (not 2D)
>^summary

# PDF
![[01. PORT Meta-Analysis.pdf]]